Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

Oropharynx SCC (p16/HPV−) — Definitive Treatment

Oropharynx SCC p16 / HPV − Early T1–2 N0–1 Resection + ipsilateral / bilateral neck dissection single modality if pN0–1 Definitive RT Concurrent chemoRT (for T1–2 N1) alternative Resectable locally advanced T3–4 · N2–3 Surgery + neck dissection Neoadjuvant pembrolizumab PD-L1 CPS ≥1, except N0 — KEYNOTE-689 ↗ Surgery → RT + pembrolizumab (+ cisplatin if ECE / + margin) → adjuvant pembrolizumab Definitive concurrent chemoRT (cisplatin) Adjuvant therapy by pathologic risk pN0, no adverse features observe pN1, no other risk consider RT Extranodal extension ± positive margin chemoRT (cisplatin) Positive margin re-resect, or RT / chemoRT Other risk features RT ± concurrent chemo